IFNB1 and myeloid sarcoma: Serum levels of 25-hydroxy vitamin D in IFN-β-treated MS patients averaged 28.8 ± 2.7 ng/ml (72.0 ± 6.8 nmol/L; median, 29 ng/ml), near the 30 ng/ml “sufficient“ threshold.